MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/hep.0000000000001167

Медицинская библиотека · Hepatology (Baltimore, Md.) · 2024

Plasma FSTL-1 as a noninvasive diagnostic biomarker for patients with advanced liver fibrosis.

Li Wenzhu, Chi Yongquan, Xiao Xuan, Li Junda, Sun Mingmin, Sun Shanke, Xu Wei, Zhang Long, Li Xiaoguo, Cheng Feng, Qi Xiaolong, Rao Jianhua

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Reliable novel noninvasive biomarkers for the diagnosis of advanced liver fibrosis are urgently needed in clinical practice. We aimed to investigate the accuracy of plasma Follistatin-like protein 1 (FSTL-1) in the diagnosis of advanced liver fibrosis in chronic liver diseases.

APPROACH AND

RESULTS

We collected cross-sectional clinical data for a derivation cohort (n = 86) and a validation cohort (n = 431), totaling 517 subjects with liver biopsy. Advanced liver fibrosis was defined by the METAVIR pathological score (F ≥3). Dual cutoff values for diagnosis were explored. In the derivation cohort, plasma FSTL-1 levels were significantly elevated in patients with advanced liver fibrosis, with an AUROC of 0.85 (95% CI, 0.75-0.96). In the validation cohort, plasma FSTL-1 maintained good diagnostic performance, with an AUROC of 0.88 (95% CI, 0.83-0.92). Plasma FSTL-1 levels were significantly associated with individual histological features of the METAVIR scoring system, including interface hepatitis, lobular necrosis, and hepatocellular ballooning (p < 0.0001). A cutoff value ≤ 0.43 ng/mL was the optimal rule-out threshold, with a sensitivity of 84.62% (95% CI, 76.46%-90.30%) and a specificity of 79.51% (95% CI, 74.81%-83.53%), while ≥0.50 ng/mL was the best rule-in threshold, with a specificity of 86.41% (95% CI, 81.06%-90.43%) and a sensitivity of 70.67% (95% CI, 64.41%-76.23%).

CONCLUSIONS

Plasma FSTL-1 has high diagnostic accuracy and could potentially reduce the need for liver biopsy in identifying patients with advanced liver fibrosis.

Для цитирования: Li Wenzhu, Chi Yongquan, Xiao Xuan, Li Junda, Sun Mingmin, Sun Shanke, Xu Wei, Zhang Long, Li Xiaoguo, Cheng Feng, Qi Xiaolong, Rao Jianhua. Plasma FSTL-1 as a noninvasive diagnostic biomarker for patients with advanced liver fibrosis.. Hepatology (Baltimore, Md.). 2024. DOI: 10.1097/hep.0000000000001167.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.